NCT07930247 Blood Pressure Control and Safety of Ex-one or Ex-one Plus in Essential Hypertension
| NCT ID | NCT07930247 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HK inno.N Corporation |
| Condition | Essential Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,525 participants |
| Start Date | 2026-05-21 |
| Primary Completion | 2031-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,525 participants in total. It began in 2026-05-21 with a primary completion date of 2031-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the proportion of patients with essential hypertension who achieve blood pressure control rates at Week 24 following treatment with Ex-one tablets or Ex-one Plus tablets, and to collect safety information observed during the study period.
Eligibility Criteria
Inclusion Criteria: 1. Aged 19 years or older 2. Patients for whom a decision has been made to administer the study medication for the treatment of essential hypertension in accordance with the approved prescribing information 3. Patients who voluntarily provide written informed consent Exclusion Criteria: 1. Patients for whom administration of the study medication is contraindicated according to the approved prescribing information 2. Patients whom the investigator considers medically unsuitable for participation in this study for reasons other than those specified above
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07930247 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Essential Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07930247 currently recruiting?
Yes, NCT07930247 is actively recruiting participants. Contact the research team at yongan.jeong@inno-n.com for enrollment information.
Where is the NCT07930247 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07930247 clinical trial?
NCT07930247 is sponsored by HK inno.N Corporation. The trial plans to enroll 7,525 participants.